Print the page
Increase font size
Red Turns to Green

Posted September 22, 2021

Aaron Gentzler

By Aaron Gentzler

Red Turns to Green

“Monday was an ugly day in the markets, no doubt about that,” says our science and technology authority Ray Blanco.

“We had the Dow down over 600 points, the Nasdaq down over 2%, and the S&P not much better.

“But I think it’s always important to point out the silver linings of these situations,” he says.

“When you have a deep red day like we saw Monday, there are almost always pockets of green to be found. And usually, those outperformers are biotech stocks.

“Even on days when the market is going through a broad correction, you can still make a lot of money trading biotech companies working on cutting-edge technologies. Especially if there is a bullish catalyst involved…

Send your opinions to, TheRundownFeedback@StPaulResearch.com

Your Rundown for Wednesday, September 22, 2021...

Novel Therapy Initiates Immune Response

“One company I’d like to talk about in particular is Innate Pharmaceuticals (IPHA),” says Ray.

“Innate is working on a cutting-edge platform that uses your own killer immune system cells, cells that are part of your innate immune system.

“Our immune systems are made up of two parts, the adaptive immune system, and the innate immune system.

“Your adaptive immune system works when it’s engaged, for example, by a vaccine. When you get a vaccine, your immune system adapts to the antigens in it,” Ray explains. “Then, if you are exposed to the pathogen, your immune system is already adapted to it. Allowing your body to fight the pathogen off more effectively.

“Your innate immune system, however, is there as a first response to any unusual activity going on in the body, like cancer cells. And this is exactly what Innate Pharmaceuticals is working on.

“Research has shown that there is a relation between the immune system and cancer treatment -- we just didn’t really know how to engage the immune system's help until recently.

“Medical technology already has cancer treatment platforms based on the adaptive immune system, but Innate Pharmaceuticals is working on a platform that utilizes your innate immune system.

“They have a plethora of therapies. Most of which are antibody therapies that work in various ways when responding to cancer cells,” Ray says. “And in early September, they announced that they will be presenting at the European Society for Medical Oncology.

“So far, their data has shown strong promise in their therapies' ability to combat cancer cells. They also have partnerships with the bigger pharmaceutical companies to help facilitate their research.

“Last, the stock has finally entered an uptrend breakout after a sleepy start earlier this year.

“All this to say IPHA is a small speculative biotech play,” Ray cautions. “It can move big, up and down, on data. So keep that in mind if you plan on trading this company.”

Market Rundown for Wednesday, Sept. 22, 2021

S&P 500 futures are up 25 points to 4,370.

Oil is up 87 cents to $71.36 for a barrel of WTI.

Gold’s down $4.20 to $1,774.10 per ounce.

Bitcoin is up $70 to $42,185 at the time of writing.

Send your comments and questions to, TheRundownFeedback@StPaulResearch.com

Have a great rest of your day… Check back Friday.

For The Rundown,

Aaron Gentzler

Aaron Gentzler
Editor, The Rundown
TheRundownFeedback@StPaulResearch.com

Pot’s SAFE Passage (Via Defense Spending?)

Pot’s SAFE Passage (Via Defense Spending?)

Posted October 20, 2021

By Aaron Gentzler

“Cannabis stocks surged in late September,” says pot stock authority Ray Blanco, “as the House voted on the National Defense Authorization Act.”
Trends and Tickers

Trends and Tickers

Posted October 18, 2021

By Aaron Gentzler

Which automaker is Tesla’s “strongest competitor”... according to Elon Musk?
   Facebook’s Metaverse Architecture

Facebook’s Metaverse Architecture

Posted October 15, 2021

By Aaron Gentzler

DeFi picks up where fintech left off…
9-1-1 Antiviral Approval

9-1-1 Antiviral Approval

Posted October 13, 2021

By Aaron Gentzler

There’s a lot of optimism surrounding Merck’s antiviral drug molnupiravir and its potential FDA approval, but is it a portfolio “keeper”?

9-1-1 Approval

Posted October 11, 2021

By Aaron Gentzler

We start off the week with news drugmaker Merck & Co. (MRK) has petitioned the FDA for emergency approval…
Brazil Embraces Bitcoin

Brazil Embraces Bitcoin

Posted October 08, 2021

By Aaron Gentzler

“Data I’ve seen recently suggest that Bitcoin is supply-constrained right now,” says our quantitative analyst Jonas Elmerraji.